The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

People in the study who were using Zepbound lost about 50% more weight those who got Wegovy, making it the superior drug in terms of weight loss. One curious thing about the study was that all the ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Eli Lilly has announced that its Zepbound (tirzepatide) was superior to Novo Nordisk’s Wegovy (semaglutide) across all weight reduction targets in a head-to-head study of the two approved weight loss ...